Findings

What do systematic reviews say?

51 questions · 57 findings · 4 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 45 · 78.9%Very low 7 · 12.3%Low 2 · 3.5%Moderate 3 · 5.3%High 0 · 0%

Iseganan vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
no estimate extracted
2 studies
GRADE not reported

Epidermal growth factor vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Epidermal growth factor led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.67 [0.45, 0.99]
1 study · 103 participants
GRADE not reported

Pentoxifylline vs no treatment

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Pentoxifylline showed no clear difference in oral mucositis (moderate to severe) compared with no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1 [0.68, 1.47]
1 study · 140 participants
GRADE not reported

Glutamine vs placebo or usual care

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Glutamine showed no clear difference in oral mucositis (moderate to severe) compared with placebo/usual care; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.88 [0.69, 1.12]
5 studies
GRADE not reported

Indomethacin vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Indomethacin showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1 [0.82, 1.23]
1 study · 18 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.71 [0.47, 1.07]
1 study · 66 participants
GRADE not reported

Camomile vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Camomile showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.63 [0.33, 1.22]
1 study · 164 participants
GRADE not reported

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.78 [0.4, 1.49]
1 study · 28 participants
GRADE not reported

Debridement vs no debridement

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
Debridement vs no debridement (Cubukcu 2007): statistically significant benefit for decreased mucositis severity; no numeric estimate reported
1 study
GRADE not reported

Gelclair vs Sucralfate and mucaine

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Gelclair showed no clear difference in mucositis severity (mild to moderate) compared with sucralfate and mucaine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.50 [0.17, 1.46]
1 study · 20 participants
GRADE not reported

Low‐level laser therapy vs Placebo (sham) laser therapy

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Low level laser therapy led to higher mucositis severity (mild to moderate) compared with sham (placebo) laser treatment; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 5.28 [2.30, 12.13]
2 studies · 57 participants
GRADE not reported